CASP6 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of A2780 ovarian carcinoma cells with targeted disruption of the CASP6 gene. This heterogeneous knockout pool enables loss-of-function analysis of caspase-6 without the selection biases of clonal isolates, providing a robust model for studying apoptosis and related pathways in an epithelial ovarian cancer context.
The A2780 cell line originates from an untreated patient with high-grade serous ovarian carcinoma and displays epithelial morphology. Widely used in ovarian cancer research, A2780 cells retain key oncogenic features and responsiveness to chemotherapeutics, making them suitable for drug evaluation and mechanistic studies of cell death pathways. By introducing a CASP6 knockout into this background, researchers can specifically interrogate caspase-6 functions in a clinically relevant cancer model.
Caspase-6 is an executioner caspase that cleaves nuclear and cytoskeletal substrates, including lamin A/C, PARP1, and cytokeratins, to orchestrate apoptotic cell dismantling. It is activated by initiator caspases CASP8 and CASP9 downstream of death receptor and mitochondrial pathways, respectively. The mitochondrial pathway involves cytochrome c, APAF1, and pro-caspase-9, while the extrinsic pathway is triggered by death receptors such as Fas. Caspase-6 interacts with other executioner caspases (CASP3, CASP7) and is regulated by IAPs like XIAP. Beyond apoptosis, caspase-6 mediates non-apoptotic processes in neuronal degeneration and inflammation, implicating it in neurodegenerative and autoimmune diseases.
Disruption of CASP6 in A2780 cells abolishes its executioner activity, enabling dissection of caspase-6-dependent apoptosis and non-apoptotic functions in ovarian carcinoma. This model is instrumental for studying apoptotic resistance mechanisms in cancer and for screening therapeutic agents that rely on caspase-6 activation to induce cell death. It also facilitates exploration of caspase-6??s role in inflammation and tumor microenvironment interactions.
Key applications include apoptosis assays (Annexin V/PI, TUNEL), fluorogenic caspase activity measurements, Western blotting for cleaved caspase-6 and substrates like lamin A/C and PARP1, immunofluorescence for nuclear lamina integrity, and RT-qPCR for CASP6 transcript quantification. The cells support drug screening, mechanistic studies of apoptosis pathways, and modeling of neurodegenerative and inflammatory processes. For further information, please contact Ascent Research.
